CClinicalTrials.gg
CompletedNCT06252350CERROS - PilotUpdated Mar 12, 2024

CERROS Pilot Study

An observational study in Coronary Artery Disease, Myocardial Infarction and Coronary Disease, sponsored by Angiowave Imaging. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-12.

Sponsored by Angiowave Imaging · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
20
Ages
18 Years and older
Sex
All
01

Study summary

The primary objective of this study is to determine whether a reduced radiation protocol (RRP) in which angiograms are acquired at ultralow radiation doses and then processed using spatiotemporal enhancement software can produce similar quality angiographic images as compared with standard techniques.

Read the detailed description

Coronary angiography is an essential diagnostic tool for determining the presence and severity of coronary artery disease, a leading cause of morbidity and mortality worldwide. While the basic techniques of coronary angiography have remained unchanged, the field of medical imaging has undergone significant advancements in hardware and software, offering new possibilities for enhanced visualization of the coronary arteries, better diagnostic accuracy, and improved patient and staff safety. However, the use of radiation during coronary angiography, which is necessary for image acquisition, exposes patients, physicians, and staff to potential risks, including radiation-induced tissue damage and an increased long-term risk of cancer. While the risks to patients attributable to the relatively low radiation doses they receive during single catheterization procedures are minimal, the cumulative risks of occupational radiation exposure are higher among physicians and staff, who are repetitively exposed to scattered radiation on a daily basis and accumulated over the course of years working in the catheterization laboratory. This occupational radiation exposure has been associated with an increased risk of cataracts, premature atherosclerosis, and certain cancers among physicians and staff. There is therefore a pressing need to explore strategies to minimize radiation doses used during coronary angiography without compromising the diagnostic accuracy of coronary artery disease detection.

Recent advancements in computational power and image processing algorithms provide opportunities for substantial reductions in radiation doses used during coronary angiography. One such advancement is spatiotemporal enhancement processing (STEP) which improves the signal to noise ratio of time sequenced angiographic data and enhances the visibility of vascular structure. This innovative STEP technique has the promise of minimizing patient and operator radiation exposure while maintaining adequate image quality. The purpose of this pilot study is to investigate a novel strategy of radiation dose reduction and data processing in coronary angiography. This pilot study will be performed in patients undergoing clinically-indicated diagnostic coronary angiography.

The study will compare angiograms acquired at ultralow radiation doses and processed with spatiotemporal enhancement software (STEP-angiograms) to standard of care angiograms (SOC-angiograms) acquired with normal radiation dose settings and no additional processing. The objectives are to assess offline whether the low radiation STEP-angiograms are of equivalent diagnostic quality as SOC-angiograms. In future research studies, the STEP software will be tested in the clinical setting to evaluate how the software may improve patient safety, enhance the overall quality of care, promote the responsible use of radiation in coronary angiography procedures, and reduce occupational radiation doses among physician and staff in the catheterization laboratory.

02

Conditions studied

  • Coronary Artery Disease
  • Myocardial Infarction
  • Coronary Disease
  • Coronary Stenosis
  • Angina Pectoris
  • Chest Pain

Keywords

  • CAD
  • Coronary
  • Angina
  • PCI
  • Angiography
03

In context

Coronary Artery Disease

5,600 studies on the registry are indexed under Coronary Artery Disease; 958 are open to participants now.

This study's enrollment of 20 is below the median of 336 across 1,947 observational studies indexed under Coronary Artery Disease.

Browse Coronary Artery Disease studies →

Lead sponsor

Angiowave Imaging is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients suspected to have coronary artery disease (CAD) who are undergoing diagnostic coronary angiography with or without possible percutaneous coronary intervention (PCI).

Inclusion criteria

  • Referred for clinically indicated coronary angiography
  • ≥18 years of age
  • Not pregnant
  • English speaking
  • Not imprisoned
  • Able to provide written informed consent

Exclusion criteria

Exclusion Criteria:

  • Hemodynamically or electrically unstable.
  • Indication for coronary angiography is emergent, including ST-segment elevation myocardial infarction
  • History of coronary artery bypass grafting
  • An eGFR \<60
  • Pregnant or lactating
  • A BMI of 45 or greater
  • Any other factor that the investigator feels would put the patient at increased risk or otherwise make the patient unsuitable for participation in the protocol.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
20 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Segment-level percent diameter stenosis (%DS)

    Segment-level quantitative coronary angiography (QCA) determination of percent diameter stenosis (%DS)

    Time frame: Periprocedural

Secondary outcomes

  1. Stenosis severity

    Agreement in reader-adjudication of segment-level identification of mild/intermediate/severe stenosis

    Time frame: Periprocedural

  2. Diagnostic quality

    Percent of coronary segments qualitatively determined to be of adequate diagnostic image quality

    Time frame: Periprocedural

  3. Radiation dose - SOC

    Radiation dose (air kerma and dose-area product) for SOC-angiograms

    Time frame: Periprocedural

  4. Radiation dose - STEP

    Radiation dose (air kerma and dose-area product) for STEP-angiograms

    Time frame: Periprocedural

07

Study locations

1 site
  • Corewell Health West
    Grand Rapids, Michigan 49503, United States
08

References and documents

Publications

  • Ryan TJ. The coronary angiogram and its seminal contributions to cardiovascular medicine over five decades. Circulation. 2002 Aug 6;106(6):752-6. doi: 10.1161/01.cir.0000024109.12658.d4. No abstract available. PubMed 12163439 ↗
  • The 2007 Recommendations of the International Commission on Radiological Protection. ICRP publication 103. Ann ICRP. 2007;37(2-4):1-332. doi: 10.1016/j.icrp.2007.10.003. PubMed 18082557 ↗
  • Valentin J. Avoidance of radiation injuries from medical interventional procedures. Ann ICRP. 2000;30(2):7-67. doi: 10.1016/S0146-6453(01)00004-5. PubMed 11459599 ↗
  • Andreassi MG, Cioppa A, Botto N, Joksic G, Manfredi S, Federici C, Ostojic M, Rubino P, Picano E. Somatic DNA damage in interventional cardiologists: a case-control study. FASEB J. 2005 Jun;19(8):998-9. doi: 10.1096/fj.04-3287fje. Epub 2005 Mar 31. PubMed 15802491 ↗
  • Karatasakis A, Brilakis HS, Danek BA, Karacsonyi J, Martinez-Parachini JR, Nguyen-Trong PJ, Alame AJ, Roesle MK, Rangan BV, Rosenfield K, Mehran R, Mahmud E, Chambers CE, Banerjee S, Brilakis ES. Radiation-associated lens changes in the cardiac catheterization laboratory: Results from the IC-CATARACT (CATaracts Attributed to RAdiation in the CaTh lab) study. Catheter Cardiovasc Interv. 2018 Mar 1;91(4):647-654. doi: 10.1002/ccd.27173. Epub 2017 Jul 14. PubMed 28707381 ↗

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Sap, Icf, Csr, Analytic code

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06252350
Lead sponsor
Angiowave Imaging
Responsible party
Sponsor
First posted
Feb 9, 2024
Start date
Feb 22, 2024
Primary completion
Mar 8, 2024
Completion
Mar 8, 2024
Last update
Mar 12, 2024

Study contacts

Ryan D Madder, MD
principal investigator · Corewell Health
Sean P Madden, PhD
study director · Angiowave Imaging
Aram Salzman
study chair · Angiowave Imaging

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion